glp 1 multiple endocrine neoplasia Semaglutide: What we know about safety and cancer risk Glucagon-like peptide 1 receptor agonists
Description
doi: 10.1152/ajpendo.00569.2013 101 RangwalaSMDAquinoKZhangYMBaderLEdwardsWZhengSet al
July, 2023
As global obesity rates continue to climb, so does the demand for effective, long-term pharmacological solutions beyond lifestyle interventions
Li ZY, Zhang N, Wen S, Zhang J, Sun XL, Fan XM et al (2017) Decreased glucagon-like peptide-1 correlates with abdominal pain in patients with constipation-predominant irritable bowel syndrome
This document may contain content generated with the assistance of artificial intelligence technologies
GLP-1R agonist therapy also results in favorable changes in circulating lipids, which are another important cardiovascular risk factor
